Inositol and Metformin Administration in Mediterranean Diet and Low-Carbohydrate Diets in Women With PCOS
2026年8月13日 更新者:Esra UCAR、Dicle University
Comparison of Inositol and Metformin Administration in Mediterranean Diet and Low-Carbohydrate Diets in Women With Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) is a common endocrine disorder frequently associated with obesity, insulin resistance (IR), and metabolic dysfunction.
Although lifestyle modification is recommended as first-line therapy, the optimal dietary approach for women with PCOS remains uncertain.
This randomized, controlled, open-label, parallel-group trial aims to compare the effects of a Mediterranean diet (MD) and a low-carbohydrate diet (LCD), each combined with metformin, inositol, or folic acid (active control), in obese women with PCOS and IR.
A total of 102 participants will be randomly assigned to one of six intervention groups and followed for two months.
Anthropometric measurements, body composition, biochemical parameters, and hedonic hunger will be assessed at baseline and after the intervention.
The primary outcome is the change in insulin resistance, assessed by the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), from baseline to 2 months.
Secondary outcomes include changes in body composition, metabolic and biochemical parameters, and hedonic hunger.
研究概览
地位
尚未招聘
详细说明
Polycystic ovary syndrome (PCOS) is a complex and widespread endocrine disorder of unknown etiology, affecting 5-20% of women of reproductive age worldwide according to different diagnostic criteria.
According to the Rotterdam criteria, PCOS is characterized by the presence of two of the following: hyperandrogenism, chronic anovulation, and polycystic ovary morphology.
While the causes of PCOS are not yet fully defined, insulin resistance (IR) is considered one of the key etiological components.
IR, frequently observed in PCOS, often mediates increased total and abdominal fat accumulation.
The close relationship between PCOS, hyperandrogenism, hyperinsulinemia, and IR also increases the risk of metabolic syndrome.
As a result of the lifelong pathological condition of PCOS, these women are at high risk for obesity, metabolic dysfunction, vascular dysfunction, malignancy, reproductive complications, and mood disorders.
For many years, effective methods have been sought to treat hormonal imbalances associated with PCOS in order to restore regular menstrual cycles and ovulation.
It has been reported that women with PCOS should reduce their energy intake through diet and implement dietary models that promote weight loss.
While various dietary interventions in the literature, such as the ketogenic diet (KD), low-carbohydrate diet (LCD), and Mediterranean diet (MD), have shown positive effects on PCOS as a first-line treatment method, the definition of PCOS-specific medical nutritional therapy is not clear.
Since PCOS is a chronic disease requiring lifelong management, and considering the side effect profile and difficulty of implementing the ketogenic diet, which appears promising in the short term, this study will evaluate the effects of the Mediterranean diet and a non-ketogenic low-carbohydrate diet.
Metformin and inositol treatments will also be included in this comparison, and thanks to an active control group (folic acid), the effect of these dietary models alone against these pharmacological treatments can also be examined.
This will allow for the evaluation of the effects of existing treatment approaches both individually and in combination.
The study is designed as a randomized controlled, open-label, parallel design.
The study will include 102 obese women diagnosed with PCOS and insulin resistance, who will be randomly assigned to two diet groups (AD and DKD).
Each diet group will be further divided into three subgroups, and these subgroups will also receive metformin, inositol, or active control (folic acid) treatments.
The intervention period of the study is two months, and adherence to diet and medication will be monitored at regular intervals.
Biochemical findings, anthropometric measurements, body composition measurements, and the Nutritional Power Scale will be repeated at the beginning and end of the two-month study.
The findings of this study will contribute to determining the optimal sequence or combination of dietary models, increasingly common food supplements, and existing medical agents in terms of treatment effectiveness.
研究类型
介入性
注册 (估计的)
90
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Esra Ucar, MSc
- 电话号码:+90 555 993 1894
- 邮箱:esra.ucar@dicle.edu.tr
学习地点
-
-
Diyarbakır
-
Diyarbakır、Diyarbakır、土耳其(türkiye)、21280
- Dicle University Hospital
-
接触:
- Elif Agacayak, MD
- 电话号码:+90 505 943 3449
- 邮箱:drelifagacayak@gmail.com
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
接受健康志愿者
不
描述
Inclusion Criteria:
- Women aged 20-40
- Diagnosed with PCOS (Rotterdam, 2004)
- Insulin resistant (newly diagnosed or diagnosed within the last 3 months)
- Obese according to the World Health Organization (2006) in grades 1 and 2 (BMI: 30-40 kg/m²)
Exclusion Criteria:
- Pregnant or breastfeeding women
- Those undergoing/contemplating IVF treatment
- Early menopause diagnosis
- Diabetes diagnosis, use of oral antidiabetic agents
- Chronic diseases (liver, kidney diseases, cancer)
- Psychiatric illnesses
- Those taking routine medication for any reason
- Use of hormonal contraceptive methods within the last 3 months
- Active smokers and alcohol users or social drinkers
- Change in body weight of more than 10% in the last 6 months for any reason
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Group Receiving Mediterranean Diet and Inositol Supplement
Participants in this arm will receive a hypocaloric Mediterranean diet combined with a myo-inositol supplement containing folic acid.
The supplement will be administered orally as two sachets daily, providing a total daily dose of 4000 mg myo-inositol and 400 µg folic acid.
The intervention period will be 2 months.
|
Myo-inositol will be administered orally as a powdered sachet formulation.
Participants will receive two sachets daily for 2 months, providing a total daily dose of 4000 mg myo-inositol and 400 µg folic acid.
Participants will receive individualized hypocaloric Mediterranean diet counseling for 2 months.
Daily energy requirements will be calculated individually, and meal plans will be prescribed with an energy deficit of approximately 500 kcal/day to promote weight loss.
The dietary pattern will emphasize vegetables, fruits, whole grains, legumes, nuts, olive oil as the principal source of fat, moderate consumption of fish, poultry, and low-fat dairy products, and limited consumption of red and processed meat, refined grains, and foods high in added sugars and saturated fat.
Dietary adherence will be monitored at regular follow-up visits throughout the intervention period.
|
|
实验性的:Group Receiving Mediterranean Diet and Metformin Treatment
Participants in this arm will receive a hypocaloric Mediterranean diet combined with metformin and folic acid supplementation.
Metformin will be administered orally at a dose of 500 mg once daily during the first week and increased to 1000 mg/day (500 mg twice daily) from the second week onward, as tolerated.
Folic acid will be administered orally at a dose of 400 µg once daily.
Folic acid is included to standardize folate intake across intervention groups, as the myo-inositol supplement used in the inositol groups also contains folic acid.
The intervention period will be 2 months.
|
Participants will receive individualized hypocaloric Mediterranean diet counseling for 2 months.
Daily energy requirements will be calculated individually, and meal plans will be prescribed with an energy deficit of approximately 500 kcal/day to promote weight loss.
The dietary pattern will emphasize vegetables, fruits, whole grains, legumes, nuts, olive oil as the principal source of fat, moderate consumption of fish, poultry, and low-fat dairy products, and limited consumption of red and processed meat, refined grains, and foods high in added sugars and saturated fat.
Dietary adherence will be monitored at regular follow-up visits throughout the intervention period.
Metformin will be administered orally for 2 months.
Treatment will begin at 500 mg once daily during the first week and will be increased to 1000 mg/day (500 mg twice daily) from the second week onward, as tolerated.
Dose escalation is intended to improve gastrointestinal tolerability while achieving the target maintenance dose.
Folic acid will be administered orally at a dose of 400 µg once daily for 2 months.
Folic acid is provided to participants in the metformin and control groups to standardize folate intake across intervention groups, as the myo-inositol supplement administered in the inositol groups also contains 400 µg of folic acid per day.
|
|
有源比较器:Mediterranean Diet Active Control Group
Participants in this arm will receive a hypocaloric Mediterranean diet together with folic acid supplementation.
Folic acid will be administered orally at a dose of 400 µg once daily.
No metformin or myo-inositol supplementation will be provided.
Folic acid is included to standardize folate intake across intervention groups, as the myo-inositol supplement used in the inositol groups also contains folic acid.
The intervention period will be 2 months.
|
Participants will receive individualized hypocaloric Mediterranean diet counseling for 2 months.
Daily energy requirements will be calculated individually, and meal plans will be prescribed with an energy deficit of approximately 500 kcal/day to promote weight loss.
The dietary pattern will emphasize vegetables, fruits, whole grains, legumes, nuts, olive oil as the principal source of fat, moderate consumption of fish, poultry, and low-fat dairy products, and limited consumption of red and processed meat, refined grains, and foods high in added sugars and saturated fat.
Dietary adherence will be monitored at regular follow-up visits throughout the intervention period.
Folic acid will be administered orally at a dose of 400 µg once daily for 2 months.
Folic acid is provided to participants in the metformin and control groups to standardize folate intake across intervention groups, as the myo-inositol supplement administered in the inositol groups also contains 400 µg of folic acid per day.
|
|
实验性的:Group Receiving Low-Carbohydrate Diet and Inositol Supplement
Participants in this arm will receive a hypocaloric low-carbohydrate diet combined with a myo-inositol supplement containing folic acid.
The supplement will be administered orally as two sachets daily, providing a total daily dose of 4000 mg myo-inositol and 400 µg folic acid.
The intervention period will be 2 months.
|
Myo-inositol will be administered orally as a powdered sachet formulation.
Participants will receive two sachets daily for 2 months, providing a total daily dose of 4000 mg myo-inositol and 400 µg folic acid.
Participants will receive individualized hypocaloric low-carbohydrate diet counseling for 2 months.
Daily energy requirements will be calculated individually, and meal plans will be prescribed with an energy deficit of approximately 500 kcal/day to promote weight loss.
The diet will provide 50-130 g/day of carbohydrates or approximately 25-30% of total daily energy from carbohydrates.
After achieving the carbohydrate target, the remaining energy intake will be distributed to provide approximately 15-30% of total energy from protein and 35-50% from fat, according to individual energy requirements.
Dietary adherence will be monitored at regular follow-up visits throughout the intervention period.
|
|
实验性的:Group Receiving Low-Carbohydrate Diet and Metformin Treatment
Participants in this arm will receive a hypocaloric low-carbohydrate diet combined with metformin and folic acid supplementation.
Metformin will be administered orally at a dose of 500 mg once daily during the first week and increased to 1000 mg/day (500 mg twice daily) from the second week onward, as tolerated.
Folic acid will be administered orally at a dose of 400 µg once daily.
Folic acid is included to standardize folate intake across intervention groups, as the myo-inositol supplement used in the inositol groups also contains folic acid.
The intervention period will be 2 months.
|
Metformin will be administered orally for 2 months.
Treatment will begin at 500 mg once daily during the first week and will be increased to 1000 mg/day (500 mg twice daily) from the second week onward, as tolerated.
Dose escalation is intended to improve gastrointestinal tolerability while achieving the target maintenance dose.
Folic acid will be administered orally at a dose of 400 µg once daily for 2 months.
Folic acid is provided to participants in the metformin and control groups to standardize folate intake across intervention groups, as the myo-inositol supplement administered in the inositol groups also contains 400 µg of folic acid per day.
Participants will receive individualized hypocaloric low-carbohydrate diet counseling for 2 months.
Daily energy requirements will be calculated individually, and meal plans will be prescribed with an energy deficit of approximately 500 kcal/day to promote weight loss.
The diet will provide 50-130 g/day of carbohydrates or approximately 25-30% of total daily energy from carbohydrates.
After achieving the carbohydrate target, the remaining energy intake will be distributed to provide approximately 15-30% of total energy from protein and 35-50% from fat, according to individual energy requirements.
Dietary adherence will be monitored at regular follow-up visits throughout the intervention period.
|
|
有源比较器:Low-Carbohydrate Diet Active Control Group
Participants in this arm will receive a hypocaloric low-carbohydrate diet together with folic acid supplementation.
Folic acid will be administered orally at a dose of 400 µg once daily.
No metformin or myo-inositol supplementation will be provided.
Folic acid is included to standardize folate intake across intervention groups, as the myo-inositol supplement used in the inositol groups also contains folic acid.
The intervention period will be 2 months.
|
Folic acid will be administered orally at a dose of 400 µg once daily for 2 months.
Folic acid is provided to participants in the metformin and control groups to standardize folate intake across intervention groups, as the myo-inositol supplement administered in the inositol groups also contains 400 µg of folic acid per day.
Participants will receive individualized hypocaloric low-carbohydrate diet counseling for 2 months.
Daily energy requirements will be calculated individually, and meal plans will be prescribed with an energy deficit of approximately 500 kcal/day to promote weight loss.
The diet will provide 50-130 g/day of carbohydrates or approximately 25-30% of total daily energy from carbohydrates.
After achieving the carbohydrate target, the remaining energy intake will be distributed to provide approximately 15-30% of total energy from protein and 35-50% from fat, according to individual energy requirements.
Dietary adherence will be monitored at regular follow-up visits throughout the intervention period.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) from Baseline to 2 Months
大体时间:Baseline and 2 months
|
Insulin resistance will be assessed using the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), calculated from fasting plasma glucose and fasting serum insulin concentrations.
The primary outcome will be the change in HOMA-IR from baseline to 2 months.
Lower HOMA-IR values indicate improved insulin sensitivity.
|
Baseline and 2 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Body Weight From Baseline to 2 Months
大体时间:Baseline and 2 months
|
Body weight will be measured in kilograms (kg).
Change in body weight will be calculated as the value at 2 months minus the baseline value.
|
Baseline and 2 months
|
|
Change in Body Mass Index From Baseline to 2 Months
大体时间:Baseline and 2 months
|
Body mass index (BMI) will be calculated as body weight in kilograms divided by height in meters squared (kg/m²).
Change in BMI will be calculated as the value at 2 months minus the baseline value.
|
Baseline and 2 months
|
|
Change in Body Fat Percentage From Baseline to 2 Months
大体时间:Baseline to 2 Months
|
Body fat percentage will be assessed by bioelectrical impedance analysis (BIA) and reported as a percentage (%).
Change in body fat percentage will be calculated as the value at 2 months minus the baseline value.
|
Baseline to 2 Months
|
|
Change in Body Fat Mass From Baseline to 2 Months
大体时间:Baseline to 2 Months
|
Body fat mass will be assessed by bioelectrical impedance analysis (BIA) and reported in kilograms (kg).
Change in body fat mass will be calculated as the value at 2 months minus the baseline value.
|
Baseline to 2 Months
|
|
Change in Fasting Serum Visfatin Concentration (ng/mL) From Baseline to 2 Months
大体时间:Baseline to 2 Months
|
Fasting serum visfatin concentration will be measured in nanograms per milliliter (ng/mL) using an enzyme-linked immunosorbent assay (ELISA).
The outcome will be reported as the change in serum visfatin concentration from baseline to 2 months, calculated as the 2-month value minus the baseline value.
|
Baseline to 2 Months
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年8月20日
初级完成 (估计的)
2026年10月1日
研究完成 (估计的)
2027年6月1日
研究注册日期
首次提交
2026年8月7日
首先提交符合 QC 标准的
2026年8月13日
首次发布 (实际的)
2026年8月18日
研究记录更新
最后更新发布 (实际的)
2026年8月18日
上次提交的符合 QC 标准的更新
2026年8月13日
最后验证
2026年7月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 泌尿生殖系统疾病
- 生殖器疾病
- 内分泌系统疾病
- 营养失调
- 肿瘤
- 女性泌尿生殖系统疾病
- 女性泌尿生殖系统疾病和妊娠并发症
- 代谢性疾病
- 营养过剩
- 体重
- 生殖器疾病,女性
- 葡萄糖代谢紊乱
- 卵巢疾病
- 附件疾病
- 性腺疾病
- 高胰岛素血症
- 超重
- 卵巢囊肿
- 囊肿
- 病理状况、体征和症状
- 营养代谢疾病
- 体征和症状
- 肥胖
- 多囊卵巢综合征
- 胰岛素抵抗
- 有机化学品
- 杂环化合物
- 杂环化合物,2环
- 杂环化合物,融合环
- 疗法
- 饮食,食物和营养
- 生理现象
- 碳水化合物
- 营养生理现象
- 酒精
- 饮食,植物性
- 饮食疗法
- 营养疗法
- 饮食
- 翼
- 翼状
- Biguanides
- 鸟齿
- 胺
- 糖醇
- 二甲双胍
- 叶酸
- 肌醇
- 饮食,地中海
- 饮食,碳水化合物限制
其他研究编号
- DU-BVD-EU-01
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
在美国制造并从美国出口的产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.